Get Started Now! Get Your Credit Repair Do It Yourself!!

Interpace Diagnostics Group Inc. (IDXG)’s Financial Results Comparing With TransUnion (NYSE:TRU)

New IdentityTheft Scam

Both Interpace Diagnostics Group Inc. (NASDAQ:IDXG) and TransUnion (NYSE:TRU) compete on a level playing field in the Business Services industry. We will evaluate their performance with regards to institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Interpace Diagnostics Group Inc. 1 -0.10 38.11M -0.44 0.00
TransUnion 81 2.09 187.49M 1.61 51.45

We can see in table 1 the earnings per share, gross revenue and valuation of Interpace Diagnostics Group Inc. and TransUnion.

Profitability

Table 2 represents Interpace Diagnostics Group Inc. (NASDAQ:IDXG) and TransUnion (NYSE:TRU)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Interpace Diagnostics Group Inc. 4,795,520,322.13% -34.7% -24.3%
TransUnion 231,269,273.47% 16.6% 4.5%

Risk and Volatility

Interpace Diagnostics Group Inc. has a 2.2 beta, while its volatility is 120.00%, thus making it more volatile than S&P 500. TransUnion has a 1.01 beta and it is 1.00% more volatile than S&P 500.

Liquidity

Interpace Diagnostics Group Inc. has a Current Ratio of 2.3 and a Quick Ratio of 2.3. Competitively, TransUnion’s Current Ratio is 1.5 and has 1.5 Quick Ratio. Interpace Diagnostics Group Inc.’s better ability to pay short and long-term obligations than TransUnion.

Analyst Ratings

The next table highlights the delivered recommendations and ratings for Interpace Diagnostics Group Inc. and TransUnion.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Interpace Diagnostics Group Inc. 0 0 1 3.00
TransUnion 0 1 3 2.75

Interpace Diagnostics Group Inc. has an average price target of $3, and a 286.55% upside potential. Competitively TransUnion has an average price target of $87.25, with potential upside of 4.55%. The data from earlier shows that analysts opinion suggest that Interpace Diagnostics Group Inc. seems more appealing than TransUnion.

Institutional & Insider Ownership

The shares of both Interpace Diagnostics Group Inc. and TransUnion are owned by institutional investors at 22.8% and 0% respectively. About 1.5% of Interpace Diagnostics Group Inc.’s share are held by insiders. Competitively, TransUnion has 0.5% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Interpace Diagnostics Group Inc. -1.84% 22.41% 17.57% -3.33% -20.91% 8.75%
TransUnion 1.58% 12.64% 22.09% 39.38% 17.18% 45.76%

For the past year Interpace Diagnostics Group Inc. was less bullish than TransUnion.

Summary

TransUnion beats Interpace Diagnostics Group Inc. on 8 of the 13 factors.

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its proprietary PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. Its customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

TransUnion provides risk and information solutions. The company operates in three segments: U.S. Information Services (USIS), International, and Consumer Interactive. The USIS segment provides consumer reports, risk scores, analytical services, and decisioning capabilities; and online data, marketing, and decision services. Its services are used to acquire new customers; assess consumer ability to pay for services; identify cross-selling opportunities; measure and manage debt portfolio risk; collect debt; verify consumer identities; and investigate potential fraud. This segment serves customers in the financial services, insurance, healthcare, and other industries. The International segment offers online data services, marketing services, credit reports, analytics, decision services, and other value-added risk management services; and consumer services, which enable consumers to manage their personal finances. This segment serves customers in financial services, insurance, automotive, collections, and communications industries through direct and indirect channels. The Consumer Interactive segment provides credit reports and scores, credit monitoring, fraud protection and resolution, and financial management solutions that enable consumers to manage their personal finances and take precautions against identity theft. This segment offers its products through online and mobile interfaces, as well as through direct and indirect channels. The company serves businesses and consumers in the United States, South Africa, Brazil, Canada, Hong Kong, and India, as well as other countries in Africa, Asia, and Latin America. The company was formerly known as TransUnion Holding Company, Inc. and changed its name to TransUnion in March 2015. TransUnion was founded in 1968 and is headquartered in Chicago, Illinois.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source: on 2019-11-02 22:35:19

Read More At Source Site

Add a Comment

Your email address will not be published. Required fields are marked *

− 1 = 1